MX2022015155A - Formulaciones y metodos para tratar la diarrea. - Google Patents

Formulaciones y metodos para tratar la diarrea.

Info

Publication number
MX2022015155A
MX2022015155A MX2022015155A MX2022015155A MX2022015155A MX 2022015155 A MX2022015155 A MX 2022015155A MX 2022015155 A MX2022015155 A MX 2022015155A MX 2022015155 A MX2022015155 A MX 2022015155A MX 2022015155 A MX2022015155 A MX 2022015155A
Authority
MX
Mexico
Prior art keywords
diarrhea
methods
secretagogue
subject
amino acid
Prior art date
Application number
MX2022015155A
Other languages
English (en)
Inventor
Sadasivan Vidyasagar
Astrid Grosche
Stephen Gatto
Xiaodong Xu
Shanshan Lin
Robert Kenefick
Samuel Cheuvront
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2022015155A publication Critical patent/MX2022015155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen en la presente descripción formulaciones de aminoácidos útiles para tratar la diarrea en un sujeto que necesita del mismo. Tales formulaciones de aminoácidos y métodos que comprenden administrar los mismos a un sujeto son útiles para tratar la diarrea, particularmente la diarrea causada por o asociada con infecciones bacterianas en donde la secreción de aniones estimulada por secretagogos de la cripta intestinal contribuye a al menos un síntoma de diarrea en el sujeto. El uso de estas formulaciones de aminoácidos para el tratamiento de la diarrea en general o la diarrea asociada con la secreción de aniones estimulada por secretagogos de la cripta intestinal se incluye en la presente descripción, así como su uso en la preparación de un medicamento para el tratamiento de la diarrea en general o la diarrea asociada con la secreción de aniones estimulada por secretagogos de la cripta intestinal.
MX2022015155A 2020-06-02 2021-06-02 Formulaciones y metodos para tratar la diarrea. MX2022015155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033697P 2020-06-02 2020-06-02
PCT/US2021/035376 WO2021247652A1 (en) 2020-06-02 2021-06-02 Formulations and methods for treating diarrhea

Publications (1)

Publication Number Publication Date
MX2022015155A true MX2022015155A (es) 2023-01-11

Family

ID=78830553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015155A MX2022015155A (es) 2020-06-02 2021-06-02 Formulaciones y metodos para tratar la diarrea.

Country Status (10)

Country Link
US (1) US20230210798A1 (es)
EP (1) EP4157304A4 (es)
JP (1) JP2023531874A (es)
KR (1) KR20230019151A (es)
CN (1) CN115916185A (es)
AU (1) AU2021284284A1 (es)
CA (1) CA3177889A1 (es)
IL (1) IL298743A (es)
MX (1) MX2022015155A (es)
WO (1) WO2021247652A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878073B1 (en) * 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372641A4 (en) * 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
KR20100089910A (ko) * 2009-02-05 2010-08-13 주식회사파마펙스 혼합 생약 추출물을 유효성분으로 함유하는 고지혈증 및 당뇨성 고지혈증의 예방 및 치료용 조성물
KR102069790B1 (ko) * 2010-09-24 2020-01-23 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
CN106146649B (zh) * 2011-09-04 2020-09-01 株式会社糖锁工学研究所 附加糖链的多肽和含有该多肽的医药组合物
CN104093410B (zh) * 2012-02-08 2018-04-27 佛罗里达大学研究基金会有限公司 用于治疗腹泻的物质和方法
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA

Also Published As

Publication number Publication date
IL298743A (en) 2023-02-01
CA3177889A1 (en) 2021-12-09
EP4157304A4 (en) 2024-06-19
AU2021284284A1 (en) 2022-11-17
KR20230019151A (ko) 2023-02-07
JP2023531874A (ja) 2023-07-26
WO2021247652A1 (en) 2021-12-09
CN115916185A (zh) 2023-04-04
EP4157304A1 (en) 2023-04-05
US20230210798A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
ES2682670T3 (es) Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas
MX2019012884A (es) Terapia de combinacion.
PH12019500360A1 (en) Antibiotic compounds
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
NZ757711A (en) Antimicrobial compounds, compositions, and uses thereof
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MX2022015155A (es) Formulaciones y metodos para tratar la diarrea.
JP2013539776A5 (es)
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
GB2546439A (en) Ezrin-derived peptides and pharmaceutical compositions thereof
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
MX2015015176A (es) Composiciones antimicrobianas y metodos para su produccion.
RU2016131197A (ru) Способ лечения или предупреждения связанных с инфекцией иммунных состояний с использованием композиции, содержащей IgM
JP2017533177A5 (es)
BR112021018219A2 (pt) Método de tratamento de endocardite infecciosa
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022008036A (es) Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.
EA202290048A1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
CA3081534A1 (en) Peptide nucleic acid molecules for treatment of gram positive bacterial infection